Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques - 1 Jan 2015

Cusato Jessica, Allegra Sarah, De Nicolò Amedeo, Boglione Lucio, Fatiguso Giovanna, Mohamed Abdi Adnan, Cariti Giuseppe, Di Perri Giovanni, D'Avolio Antonio

Abstract excerpt

PURPOSE: Triple therapy for HCV-1 infection consists in boceprevir or telaprevir, ribavirin and PEG-interferon. Telaprevir is a P-glycoprotein substrate and it is metabolized by CYP3A4/5. No data have been published on intracellular penetration of telaprevir. We determined peripheral blood mononuclear cells (PBMCs) and trough plasma S and R telaprevir isomers concentrations; moreover, we evaluated the influence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatography, High Pressure Liquid
Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oligopeptides

Share to Pharmacogenetics

Share to Real-Time Polymerase Chain Reaction

Share to Regression Analysis

Share to Ribavirin

Share to Tandem Mass Spectrometry

Source

Identifiers

PMID: 26158282
DOI: 10.18433/j3dk6t

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir.PMID 26158282Read ↗

Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics.Semantic proximity Read ↗

Telaprevir: a hepatitis C NS3/4A protease inhibitor.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.Semantic proximity Read ↗

ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy.Semantic proximity Read ↗

Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.Semantic proximity Read ↗

[Biochemical and pharmacological features of telaprevir].Semantic proximity Read ↗

Telaprevir: a new hope in the treatment of chronic hepatitis C?Semantic proximity Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].Semantic proximity Read ↗

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.Semantic proximity Read ↗

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.